# Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration

> **NCT03034772** · PHASE2,PHASE3 · COMPLETED · sponsor: **Wills Eye** · enrollment: 52 (actual)

## Conditions studied

- Neovascular Age-related Macular Degeneration
- Wet Macular Degeneration

## Interventions

- **DRUG:** Dorzolamide-timolol
- **OTHER:** Artificial tears

## Key facts

- **NCT ID:** NCT03034772
- **Lead sponsor:** Wills Eye
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-08
- **Primary completion:** 2019-02-08
- **Final completion:** 2019-07-05
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2020-06-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03034772

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03034772, "Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03034772. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*